Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

The company also has an InThrill system that removes emboli and thrombi from the peripheral vasculature ... partnership with the Institute for Follicular Lymphoma Innovation (IFLI), a non-profit ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

The availability of a follicular lymphoma data library has the potential to improve researchers' understanding of the disease's biology. Providing researchers with access to robust multimodal data ...

In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma is currently ... T-cell counts in peripheral blood (blue line) and soluble ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma ... with this advanced blood cancer," said Marie ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).